Evidence map›Paper›PMID 38956489›Full record

ArticleBMC cardiovascular disorders2024

Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries.

Haiyan Xue, Lan Wang, Yuliang Ma, Chang Hou

Abstract readCase Reports
In one paragraph

Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haiyan XueDepartment of Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Lan WangDepartment of Cardiology, Peking University People's Hospital, Beijing, China.
Yuliang MaDepartment of Cardiology, Peking University People's Hospital, Beijing, China.
Chang HouDepartment of Cardiology, Peking University People's Hospital, Beijing, China. houchang@pkuph.edu.cn.

Funding

Peking University People's Hospital Scientific Research Development Funds RDX2022-04 and RDJP2023-12
6 · The paper itself

Abstract

The anticancer drug of tyrosine kinase-inhibitors (TKIs) has significantly improved the prognosis of patients with specific leukemia but has also increased the risk of organ adverse reactions. Herein, we present a case of a patient diagnosed with myeloproliferative neoplasms who experienced recurrent chest pain after receiving treatment with Olverembatinib. Electrocardiography and coronary angiography confirmed the diagnosis of myocardial infarction with non-obstructive coronary arteries. This case serves as a reminder for clinicians to pay more attention and actively prevent the cardiac adverse reactions of TKIs when using such medications.

Indexed as

Coronary AngiographyProtein Kinase InhibitorsAntineoplastic AgentsCardiotoxicityElectrocardiographyHumansMaleMiddle AgedMyocardial InfarctionTreatment OutcomeAntineoplastic AgentsProtein Kinase InhibitorsMINOCAOlverembatinibTKI

Identifiers

PMID38956489
PMCPMC11221000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.